Year All2026202520242023202220212020 Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress June 12, 2026 Read More Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion June 8, 2026 Read More Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress June 4, 2026 Read More Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 1, 2026 Read More Lyell Immunopharma Announces Participation in May Investor Conferences May 12, 2026 Read More Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 May 6, 2026 Read More Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference April 7, 2026 Read More Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results March 12, 2026 Read More Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer March 9, 2026 Read More Lyell Immunopharma Announces Participation in March Investor Conferences February 23, 2026 Read More
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress June 12, 2026 Read More
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion June 8, 2026 Read More
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress June 4, 2026 Read More
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 1, 2026 Read More
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 May 6, 2026 Read More
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference April 7, 2026 Read More
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results March 12, 2026 Read More
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer March 9, 2026 Read More